Altered CB1 receptor-signaling in prefrontal cortex from an animal model of depression is reversed by chronic fluoxetine

Journal of Neurochemistry

Volumn 108, Issue 6, 2009, Pages 1423-1433

  Rodríguez Gaztelumendi, Antonio ^a   Rojo, Ma Luisa ^a   Pazos, Angel ^a   Díaz, Alvaro ^a  

^a UNIVERSITY OF CANTABRIA   (Spain)

Author keywords

9 tetrahydrocannabinol; 35S GTP S binding; Cannabinoid receptor 1; Fluoxetine; Olfactory bulbectomy; Prefrontal cortex

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; CANNABINOID 1 RECEPTOR; FLUOXETINE; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); TETRAHYDROCANNABINOL; 3 (2 HYDROXY 4 (1,1 DIMETHYLHEPTYL)PHENYL) 4 (3 HYDROXYPROPYL)CYCLOHEXANOL; 3-(2-HYDROXY-4-(1,1-DIMETHYLHEPTYL)PHENYL)-4-(3-HYDROXYPROPYL)CYCLOHEXANOL; ANTIDEPRESSANT AGENT; CYCLOHEXANOL DERIVATIVE; DELTA9 TETRAHYDROCANNABINOL HEMISUCCINATE; DELTA9-TETRAHYDROCANNABINOL HEMISUCCINATE; DRUG DERIVATIVE; IMMUNOSUPPRESSIVE AGENT; ISOTOPE;

ACUTE DRUG ADMINISTRATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR CHANGE; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DEPRESSION; DISEASE MODEL; HYPERACTIVITY; LOCOMOTION; NONHUMAN; OPEN FIELD TEST; PREFRONTAL CORTEX; PRIORITY JOURNAL; RAT; RECEPTOR BINDING; RECEPTOR DENSITY; SIGNAL TRANSDUCTION; ANIMAL; AUTORADIOGRAPHY; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG EFFECT; EXPLORATORY BEHAVIOR; INJURY; MALE; METABOLISM; OLFACTORY BULB; PATHOLOGY; PROTEIN BINDING; SPRAGUE DAWLEY RAT; TIME;

ANIMALIA; RATTUS;

ANIMALS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; AUTORADIOGRAPHY; CYCLOHEXANOLS; DEPRESSION; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; EXPLORATORY BEHAVIOR; FLUOXETINE; GUANOSINE 5'-O-(3-THIOTRIPHOSPHATE); IMMUNOSUPPRESSIVE AGENTS; ISOTOPES; MALE; OLFACTORY BULB; PREFRONTAL CORTEX; PROTEIN BINDING; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, CANNABINOID, CB1; SIGNAL TRANSDUCTION; TETRAHYDROCANNABINOL; TIME FACTORS;

EID: 61349092930     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2009.05898.x     Document Type: Article

References (77)

1. Bambico F. R., Katz N., Debonnel G. Gobbi G. (2007) Cannabinoids elicit antidepressant-like behavior and activate serotonergic neurons through the medial prefrontal cortex. J. Neurosci. 27, 11700 11711.
2. Banasr M. Duman R. S. (2007) Regulation of neurogenesis and gliogenesis by stress and antidepressant treatment. CNS Neurol. Disord. Drug Targets 6, 311 320.
3. Banerjee S. P., Snyder S. H. Mechoulam R. (1975) Cannabinoids: influence on neurotransmitter uptake in rat brain synaptosomes. J. Pharmacol. Exp. Ther. 194, 74 81.
4. Berrendero F. Maldonado R. (2002) Involvement of the opioid system in the anxiolytic-like effects induced by delta(9)-tetrahydrocannabinol. Psychopharmacology (Berl.) 163, 111 117.
5. Bortolato M., Mangieri R. A., Fu J. et al. (2007) Antidepressant-like activity of the fatty acid amide hydrolase inhibitor URB597 in a rat model of chronic mild stress. Biol. Psychiatry 62, 1103 1110.
6. Cairncross K. D., Cox B., Forster C. Wren A. F. (1977) The olfactory bulbectomized rat: a simple model for detecting drugs with antidepressant potential. Br. J. Pharmacol. 61, 497P.
7. 1A receptors in rat brain. Neuropharmacology 44, 93 101.
8. Chaperon F. Thiebot M. H. (1999) Behavioral effects of cannabinoid agents in animals. Crit. Rev. Neurobiol. 13, 243 281.
9. Chen C. Bazan N. G. (2005) Lipid signaling: sleep, synaptic plasticity, and neuroprotection. Prostaglandins Other Lipid Mediat. 77, 65 76.
10. Cryan J. F., Page M. E. Lucki I. (2005) Differential behavioral effects of the antidepressants reboxetine, fluoxetine, and moclobemide in a modified forced swim test following chronic treatment. Psychopharmacology (Berl.) 182, 335 344.
11. 1 receptor antagonist SR 141716A increase brain serotonin and dopamine levels and turnover. Pharmacol. Biochem. Behav. 75, 777 787.
12. Devlin M. G. Christopoulos A. (2002) Modulation of cannabinoid agonist binding by 5-HT in the rat cerebellum. J. Neurochem. 80, 1095 1102.
13. Egashira N., Matsuda T., Koushi E. et al. (2008) Delta(9)- tetrahydrocannabinol prolongs the immobility time in the mouse forced swim test: involvement of cannabinoid CB(1) receptor and serotonergic system. Eur. J. Pharmacol. 28, 117 121.
14. Egerton A., Allison C., Brett R. R. Pratt J. A. (2006) Cannabinoids and prefrontal cortical function: insights from preclinical studies. Neurosci. Biobehav. Rev. 30, 680 695.
15. 1 cannabinoid receptor expression in the mouse brain: evidence of a widespread role for fatty acid amide hydrolase in regulation of endocannabinoid signaling. Neuroscience 119, 481 496.
16. Glass M., Dragunow M. Faull R. L. (1997) Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. Neuroscience 77, 299 318.
17. Gobbi G., Bambico F. R., Mangieri R. et al. (2005) Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis. Proc. Natl Acad. Sci. USA 102, 18620 18625.
18. 35S]GTPγS binding to cortical membranes from postmortem human brain. Eur. J. Pharmacol. 390, 25 36.
19. Gray J. A. Lalljee B. (1974) Sex differences in emotional behaviour in the rat: correlation between open-field defecation and active avoidance. Anim. Behav. 22, 856 861.
20. Grecksch G., Zhou D., Franke C., Schroder U., Sabel B., Becker A. Huether G. (1997) Influence of olfactory bulbectomy and subsequent imipramine treatment on 5-hydroxytryptaminergic presynapses in the rat frontal cortex: behavioural correlates. Br. J. Pharmacol. 122, 1725 1731.
21. 1 receptor antagonist rimonabant in models of emotional reactivity in rodents. Biol. Psychiatry 57, 261 267.
22. 1A receptors in mice. Pharmacol. Biochem. Behav. 45, 65 70.
23. 1 cannabinoid receptor on anxiety. Eur. J. Neurosci. 16, 1395 1398.
24. 1-specific agents. Behav. Pharmacol. 15, 299 304.
25. Herkenham M., Lynn A. B., Johnson M. R., Melvin L. S., de Costa B. R. Rice K. C. (1991) Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J. Neurosci. 11, 563 583.
26. Hesketh S. A., Brennan A. K., Jessop D. S. Finn D. P. (2008) Effects of chronic treatment with citalopram on cannabinoid and opioid receptor-mediated G-protein coupling in discrete rat brain regions. Psychopharmacology (Berl.) 198, 26 39.
27. Hill M. N., Ho W. S., Sinopoli K. J., Viau V., Hillard C. J. Gorzalka B. B. (2006a) Involvement of the endocannabinoid system in the ability of long-term tricyclic antidepressant treatment to suppress stress-induced activation of the hypothalamic-pituitary-adrenal axis. Neuropsychopharmacology 31, 2591 2599.
28. Hill M. N., Sun J. C., Tse M. T. Gorzalka B. B. (2006b) Altered responsiveness of serotonin receptor subtypes following long-term cannabinoid treatment. Int. J. Neuropsychopharmacol. 9, 277 286.
29. Hill M. N., Barr A. M., Ho W. S., Carrier E. J., Gorzalka B. B. Hillard C. J. (2007) Electroconvulsive shock treatment differentially modulates cortical and subcortical endocannabinoid activity. J. Neurochem. 103, 47 56.
30. Hill M. N., Carrier E. J., McLaughlin R. J., Morrish A. C., Meier S. E., Hillard C. J. Gorzalka B. B. (2008) Regional alterations in the endocannabinoid system in an animal model of depression: effects of concurrent antidepressant treatment. J. Neurochem. 106, 2322 2336.
31. Hillard C. J., Hill M. N., Carrier E. J., Shi L., Cullinan W. E. Gorzalka B. B. (2006) Regulation of cannabinoid receptor expression by chronic unpredictable stress in rats and mice. Soc. Neurosci. Abstr. 746, 19.
32. Howlett A. C., Barth F., Bonner T. I. et al. (2002) International union of pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol. Rev. 54, 161 202.
33. Huang Y. L., Yu J. P., Wang G. H., Chen Z. H., Wang Q. Xiao L. (2007) Effect of fluoxetine on depression-induced changes in the expression of vasoactive intestinal polypeptide and corticotrophin releasing factor in rat duodenum. World J. Gastroenterol. 13, 6060 6065.
34. 35S]GTPγS binding in the prefrontal cortex of depressed suicide victims. Mol. Psychiatry 9, 184 190.
35. Jaako-Movits K., Zharkovsky T., Pedersen M. Zharkovsky A. (2006) Decreased hippocampal neurogenesis following olfactory bulbectomy is reversed by repeated citalopram administration. Cell. Mol. Neurobiol. 26, 1559 1570.
36. James A. N., Ryan J. P. Parkman H. P. (2005) Effects of the selective serotonin reuptake inhibitor, fluoxetine, on regional gastric contractility. Neurogastroenterol. Motil. 17, 76 82.
37. Jancsar S. M. Leonard B. E. (1984) Changes in neurotransmitter metabolism following olfactory bulbectomy in the rat. Prog. Neuropsychopharmacol. Biol. Psychiatry 8, 263 269.
38. 1 receptor antagonist SR-141716 in rats: open-field revisited. Pharmacol. Biochem. Behav. 73, 911 919.
39. Järbe T. U., Ross T., DiPatrizio N. V., Pandarinathan L. Makriyannis A. (2006) Effects of the CB1R agonist WIN-55,212-2 and the CB1R antagonists SR-141716 and AM-1387: open-field examination in rats. Pharmacol. Biochem. Behav. 85, 43 52.
40. Jarosik J., Legutko B., Unsicker K. von Bohlen Und Halbach O. (2007) Antidepressant-mediated reversal of abnormal behavior and neurodegeneration in mice following olfactory bulbectomy. Exp. Neurol. 204, 20 28.
41. Jiang W., Zhang Y., Xiao L., Van Cleemput J., Ji S. P., Bai G. Zhang X. (2005) Cannabinoids promote embryonic and adult hippocampus neurogenesis and produce anxiolytic- and antidepressant-like effects. J. Clin. Invest. 115, 3104 3116.
42. Keilhoff G., Becker A., Grecksch G., Bernstein H. G. Wolf G. (2006) Cell proliferation is influenced by bulbectomy and normalized by imipramine treatment in a region-specific manner. Neuropsychopharmacology 31, 1165 1176.
43. Kelly J. P., Wrynn A. S. Leonard B. E. (1997) The olfactory bulbectomized rat as a model of depression: an update. Pharmacol. Ther. 74, 299 316.
44. Lopez-Rubalcava C. Lucki I. (2000) Strain differences in the behavioral effects of antidepressant drugs in the rat forced swimming test. Neuropsychopharmacology 22, 191 199.
45. Lumia A. R., Teicher M. H., Salchli F., Ayers E. Possidente B. (1992) Olfactory bulbectomy as a model for agitated hyposerotonergic depression. Brain Res. 587, 181 185.
46. Malone D. T. Taylor D. A. (1998) Modulation of delta9- tetrahydrocannabinol-induced hypothermia by fluoxetine in the rat. Br. J. Pharmacol. 124, 1419 1424.
47. 9Δ-tetrahydrocannabinol-induced hypothermia in the rat. Pharmacol. Biochem. Behav. 69, 595 601.
48. Mar A., Spreekmeester E. Rochford J. (2000) Antidepressants preferentially enhance habituation to novelty in the olfactory bulbectomized rat. Psychopharmacology (Berl.) 150, 52 60.
49. Mar A., Spreekmeester E. Rochford J. (2002) Fluoxetine-induced increases in open-field habituation in the olfactory bulbectomized rat depend on test aversiveness but not on anxiety. Pharmacol. Biochem. Behav. 73, 703 712.
50. 1A receptors in behavioural effects of the cannabinoid receptor agonist CP 55,940 in male rats. Behav. Pharmacol. 15, 21 27.
51. 1 cannabinoid receptors in emotional behaviour. Psychopharmacology (Berl.) 159, 379 387.
52. Mato S. Pazos A. (2004) Influence of age, postmortem delay and freezing storage period on cannabinoid receptor density and functionality in human brain. Neuropharmacology 46, 716 726.
53. 2A/C receptors. J. Neurochem. 103, 2111 2120.
54. 1 cannabinoid receptor in the rat brain. an immunohistochemical study. Peptides 21, 1735 1742.
55. 1 receptors. Naunyn Schmiedebergs Arch. Pharmacol. 361, 19 24.
56. Nesterova I. V., Gurevich E. V., Nesterov M., Otmakhova N. A. Bobkova N. V. (1997) Bulbectomy-induced loss of raphe neurons is counteracted by antidepressant treatment. Prog. Neuropsychopharmacol. Biol. Psychiatry 21, 127 140.
57. Oliva J. M., Uriguen L., Perez-Rial S. Manzanares J. (2005) Time course of opioid and cannabinoid gene transcription alterations induced by repeated administration with fluoxetine in the rat brain. Neuropharmacology 49, 618 626.
58. 2 receptors in brain. Ann. NY Acad. Sci. 1074, 514 536.
59. Pazos A., Mostany R., Mato S. et al. (2006) Constitutive activity of cannabinoid CB1 receptors in major depression. Soc. Neurosci.Abstr. 191, 18.
60. Redmond A. M., Kelly J. P. Leonard B. E. (1997) Behavioural and neurochemical effects of dizocilpine in the olfactory bulbectomized rat model of depression. Pharmacol. Biochem. Behav. 58, 355 359.
61. Roche M., Harkin A. Kelly J. P. (2007) Chronic fluoxetine treatment attenuates stressor-induced changes in temperature, heart rate, and neuronal activation in the olfactory bulbectomized rat. Neuropsychopharmacology 32, 1312 1320.
62. 1 receptor inverse agonist AM251 in mice. Behav. Pharmacol. 14, 573 582.
63. 35S]GTPγS autoradiography in rat brain. J. Neurosci. 16, 8057 8066.
64. Slotkin T. A., Cousins M. M., Tate C. A. Seidler F. J. (2005) Serotonergic cell signaling in an animal model of aging and depression: olfactory bulbectomy elicits different adaptations in brain regions of young adult vs aging rats. Neuropsychopharmacology 30, 52 57.
65. Song C. Leonard B. E. (2005) The olfactory bulbectomised rat as a model of depression. Neurosci. Biobehav. Rev. 29, 627 647.
66. van der Stelt H. M., Breuer M. E., Olivier B. Westenberg H. G. (2005) Permanent deficits in serotonergic functioning of olfactory bulbectomized rats: an in vivo microdialysis study. Biol. Psychiatry 57, 1061 1067.
67. Stock H. S., Ford K. Wilson M. A. (2000) Gender and gonadal hormone effects in the olfactory bulbectomy animal model of depression. Pharmacol. Biochem. Behav. 67, 183 191.
68. Suplita R. L. II., Eisenstein S. A., Neely M. H., Moise A. M. Hohmann A. G. (2008) Cross-sensitization and cross-tolerance between exogenous cannabinoid antinociception and endocannabinoid-mediated stress-induced analgesia. Neuropharmacology 54, 161 171.
69. 1 receptor antagonist SR141716A selectively increases monoaminergic neurotransmission in the medial prefrontal cortex: implications for therapeutic actions. Br. J. Pharmacol. 138, 544 553.
70. 1 receptors. Neuropharmacology 46, 966 973.
71. Van Gaal L. F., Rissanen A. M., Scheen A. J., Ziegler O., Rossner S. RIO-Europe Study Group (2005) Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-europe study. Lancet 365, 1389 1397.
72. Vinod Y. Hungund B. L. (2006) Role of the endocannabinoid system in depression and suicide. Trends Pharmacol. Sci. 27, 539 545.
73. 1 receptor-mediated G-protein signaling in the prefrontal cortex of alcoholic suicide victims. Biol. Psychiatry 57, 480 486.
74. Viveros M. P., Marco E. M. File S. E. (2005) Endocannabinoid system and stress and anxiety responses. Pharmacol. Biochem. Behav. 81, 331 342.
75. 1 receptor antagonists in major depressive disorders. Trends Pharmacol. Sci. 26, 609 617.
76. Zhang Y., Raap D. K., Garcia F., Serres F., Ma Q., Battaglia G. Van de Kar L. D. (2000) Long-term fluoxetine produces behavioral anxiolytic effects without inhibiting neuroendocrine responses to conditioned stress in rats. Brain Res. 855, 58 66.
77. Zhou D., Grecksch G., Becker A., Frank C., Pilz J. Huether G. (1998) Serotonergic hyperinnervation of the frontal cortex in an animal model of depression, the bulbectomized rat. J. Neurosci. Res. 54, 109 116.